Cargando…
Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya
In a phase-IIa trial, we investigated the influence of 90 days continuous-delivery tenofovir (TFV) intravaginal rings (IVRs) with/without levonorgestrel (LNG) on the genital microbiota of Kenyan women. Eligible women (n = 27; 18–34 years; negative for HIV, sexually transmitted infections, and Amsel-...
Autores principales: | Dabee, Smritee, Mugo, Nelly, Mudhune, Victor, McLellan-Lemal, Eleanor, Peacock, Sue, O’Connor, Siobhan, Njoroge, Betty, Nyagol, Beatrice, Thurman, Andrea R., Ouma, Eunice, Ridzon, Renee, Wiener, Jeffrey, Haugen, Harald S., Gasper, Melanie, Feng, Colin, Allen, Shannon A., Doncel, Gustavo F., Jaspan, Heather B., Heffron, Renee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283538/ https://www.ncbi.nlm.nih.gov/pubmed/35835755 http://dx.doi.org/10.1038/s41598-022-13475-9 |
Ejemplares similares
-
Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya
por: Mugo, Nelly R., et al.
Publicado: (2023) -
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019) -
Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
por: Thurman, Andrea R., et al.
Publicado: (2022) -
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
por: Thurman, Andrea Ries, et al.
Publicado: (2018) -
Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration
por: Ouattara, Louise A., et al.
Publicado: (2022)